Richard F. Riedel, MD
Department / Division
Medicine /
Medicine - Oncology
Address
DUMC 3198
Durham, NC 27710
Appointment Telephone
877-727-2385
Office Telephone
919-681-6932
Fax Telephone
919-684-5163
- MD, Jefferson Medical College of Thomas Jefferson University (Pennsylvania), 2000
- Internal Medicine, Duke University Medical Center, 2000-2003
- Internal Medicine, Chief Resident, Durham VA Medical Center, 2004-2005
- Hematology-Medical Oncology, Duke University Medical Center, 2003-2004, 2005-2007
Clinical Interests
Treatment and management of patients with soft-tissue and bone sarcomas
Research Interests
Novel therapies for soft tissue and bone sarcomas
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Copernicus Group IRB (CGIRB)
- CytRx Corporation
- Merck
- Novartis
- Pfizer Inc.
Representative Publications
Riedel, RF. Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches. Cancer. 2012;118:1474-1485.
(2012)
Abstract
Palta, M; Riedel, RF; Vredenburgh, JJ; Cummings, TJ; Green, S; Chang, Z; Kirkpatrick, JP. Primary meningeal rhabdomyosarcoma. Sarcoma. 2011;2011:312802.
(2011)
Abstract
Smith, JL; Riedel, RF. Emerging therapeutic targets for soft tissue sarcoma. Current Oncology Reports. 2011;13:350-358.
(2011)
Abstract
Demetri, GD; Antonia, S; Benjamin, RS; Bui, MM; Casper, ES; Conrad, EU; DeLaney, TF; Ganjoo, KN; Heslin, MJ; Hutchinson, RJ; Kane, JM; Letson, GD; McGarry, SV; O'Donnell, RJ; Paz, IB; Pfeifer, JD; Pollock, RE; Randall, RL; Riedel, RF; Schupak, KD; Schwartz, HS; Thornton, K; von Mehren, M; Wayne, J; National Comprehensive Cancer Network Soft Tissue Sarcoma Panel. Soft tissue sarcoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2010;8:630-674.
(2010)
Abstract
Demetri, GD; von Mehren, M; Antonescu, CR; DeMatteo, RP; Ganjoo, KN; Maki, RG; Pisters, PW; Raut, CP; Riedel, RF; Schuetze, S; Sundar, HM; Trent, JC; Wayne, JD. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. Journal of the National Comprehensive Cancer Network : JNCCN. 2010;8 Suppl 2:S1-41.
(2010)
Abstract
Mito, JK; Riedel, RF; Dodd, L; Lahat, G; Lazar, AJ; Dodd, RD; Stangenberg, L; Eward, WC; Hornicek, FJ; Yoon, SS; Brigman, BE; Jacks, T; Lev, D; Mukherjee, S; Kirsch, DG. Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS One. 2009;4:e8075.
(2009)
Abstract
Riedel, RF; Larrier, N; Dodd, L; Kirsch, D; Martinez, S; Brigman, BE. The clinical management of chondrosarcoma. Current Treatment Options in Oncology. 2009;10:94-106.
(2009)
Abstract
Riedel, RF; Porrello, A; Pontzer, E; Chenette, EJ; Hsu, DS; Balakumaran, B; Potti, A; Nevins, J; Febbo, PG. A genomic approach to identify molecular pathways associated with chemotherapy resistance. Molecular Cancer Therapeutics. 2008;7:3141-3149.
(2008)
Abstract
Hsu, DS; Balakumaran, BS; Acharya, CR; Vlahovic, V; Walters, KS; Garman, K; Anders, C; Riedel, RF; Lancaster, J; Harpole, D; Dressman, HK; Nevins, JR; Febbo, PG; Potti, A. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. Journal of Clinical Oncology. 2007;25:4350-4357.
(2007)
Abstract
Riedel, RF; Andrews, C; Garst, J; Dunphy, F; Herndon, JE; Blackwell, S; Barbour, S; Crawford, J. A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology. 2007;2:520-525.
(2007)
Abstract
Riedel, RF; Burfeind, WR. Thymoma: benign appearance, malignant potential. The Oncologist. 2006;11:887-894.
(2006)
Abstract
Riedel, RF; Crawford, J; Dunphy, F; Herndon, JE; Garst, J; Kelley, MJ. Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer. Lung Cancer. 2006;54:431-432.
(2006)
Abstract
Riedel, RF; Wang, X; McCormack, M; Toloza, E; Montana, GS; Schreiber, G; Kelley, MJ. Impact of a multidisciplinary thoracic oncology clinic on the timeliness of care. Journal of Thoracic Oncology. 2006;1:692-696.
(2006)
Abstract
Riedel, RF; Febbo, PG. Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer. Future Oncology. 2005;1:461-466.
(2005)
Abstract
Riedel, RF; Crawford, J. Small-cell lung cancer: a review of clinical trials. Seminars in Thoracic and Cardiovascular Surgery. 2003;15:448-456.
(2003)
Abstract
Luetteke, NC; Qiu, TH; Fenton, SE; Troyer, KL; Riedel, RF; Chang, A; Lee, DC. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development (Cambridge). 1999;126:2739-2750.
(1999)
Abstract
Salomoni, P; Wasik, MA; Riedel, RF; Reiss, K; Choi, JK; Skorski, T; Calabretta, B. Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. Journal of Experimental Medicine. 1998;187:1995-2007.
(1998)
Abstract
